Title | Chemoradiation in Cancer Therapy [electronic resource] / edited by Hak Choy |
---|---|
Imprint | Totowa, NJ : Humana Press : Imprint: Humana Press, 2003 |
Connect to | http://dx.doi.org/10.1007/978-1-59259-325-5 |
Descript | XII, 420 p. online resource |
I. General/Background -- 1 Chemoradiation: Biological Principles and Perspectives -- 2 Fluoropyrimidines as Radiation Sensitizers -- II. Mechanisms of Interaction of Specific Chemotherapeutic Agents with Radiation -- 3 The Role of Platinum Complexes in Combined Modality Therapy -- 4 Taxanes in Combined Modality Therapy -- 5 Camptothecin Radiation Sensitization -- 6 The Role of Gemcitabine in Combined Modality Therapy -- III. Clinical Applications -- 7 Chemoradiation Strategies for Patients with Malignant Gliomas -- 8 Combined Modality Strategies in the Treatment of Head and Neck Cancer -- 9 The Role of Combined Modality Therapy for Stage III Nonsmall-Cell Lung Cancer -- 10 Combined Modality Treatment of Small-Cell Lung Cancer -- 11 The Role of Chemoradiation in the Management of Esophageal Cancer -- 12 Combined Modality Therapy in Locally Advanced Breast Cancer -- 13 Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomas -- 14 Chemoradiation in Therapy for Colon and Rectum Carcinoma -- 15 Chemoradiotherapy in Muscle-Invasive Bladder Cancer -- 16 The Role of Combined Chemotherapy and Radiation Therapy in the Treatment of Gynecologic Malignancies -- IV. Specific Molecular Targeted Agents -- 17 Overview of Specific Molecular Targeted Agents for Combined Modality Therapy -- 18 Receptor Tyrosine Kinases as Therapeutic Targets in Solid Tumors -- 19 Adenoviral p53 Gene Therapy Strategies in Nonsmall-Cell Lung Cancer -- 20 Tumor Microvasculature as a Therapeutic Target During Radiotherapy -- 21 Cancer Drug Discovery and Development: Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer -- 22 The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapy